Results 11 to 20 of about 10,900 (261)

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration

Human Vaccines & Immunotherapeutics, 2023
Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommended ...
Elizabeth R. Packnett, Isabelle H. Winer, Abiola Oladapo, Matthew Wojdyla   +3 more
doaj   +2 more sources

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

BMC Infectious Diseases
Aim Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection.
Jaime E. Ordóñez, Victor M. Huertas
doaj   +2 more sources

Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia

Journal of Infection in Developing Countries, 2021
Introduction: Respiratory syncytial virus (RSV) is one of the most important childhood infections. Objective: To evaluate the effectiveness and safety of palivizumab immunoprophylaxis in preterm infants at a high risk of severe respiratory syncytial ...
Juan Gabriel Piñeros, Jose De la Hoz-Valle, Clara Galvis, Astrid Celis, Oscar Ovalle, Carmen Cecilia Sandoval, Jaime Orrego, Saby Vides, Iader Rojas, Hernando Bustamante, Carlos Gallón, Jaime Alberto Mesa   +11 more
doaj   +2 more sources

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection

Scientific Reports, 2021
Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations.
Agata Antepowicz, Omar Habib, Freja Kirsebom, Cecilia Johansson, Deborah R. Gill, Stephen C. Hyde   +5 more
doaj   +2 more sources

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States

Pediatrics and Neonatology, 2023
Background: Respiratory syncytial virus (RSV) hospitalizations have increased since the 2014 guideline update recommended against the use of palivizumab for preterm infants born ≥29 0/7 weeks' gestational age (GA) without additional risk factors. A novel
Tianzhou Yu, William V. Padula, Leah Yieh, Cynthia L. Gong   +3 more
doaj   +2 more sources

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives. [PDF]

Pediatr Allergy Immunol
Evolution of RSV immunoprophylaxis: from the palivizumab era to next‐generation monoclonal antibodies and future perspectives. Created in BioRender. Abstract The burden of respiratory syncytial virus (RSV) remains a major global health concern in early childhood, responsible for substantial morbidity, hospitalizations, and deaths, particularly in ...
Bizot E, Portet Sulla V, Vauloup-Fellous C, Rameix-Welti MA, Gajdos V, Seddiki N.   +5 more
europepmc   +2 more sources

Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection.

Pediatrics, 2023
Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement in 1998.
M. Caserta, S. O'Leary, F. Muñoz, S. Ralston   +3 more
semanticscholar   +1 more source

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.

Cochrane Database of Systematic Reviews, 2021
BACKGROUND Respiratory viruses are the leading cause of lower respiratory tract infection (LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent in this population.
L. Garegnani, Lea Styrmisdóttir, P. Roson Rodriguez, C. E. Escobar Liquitay, I. Esteban, Juan V A Franco   +5 more
semanticscholar   +1 more source

Quantitative Analysis of Antibody Survival across the Infant Digestive Tract Using Mass Spectrometry with Parallel Reaction Monitoring

Foods, 2020
Orally delivered antibodies may be useful for the prevention of enteric pathogen infection, but to be effective they need to survive intact across digestion through the gastrointestinal tract.
Bum Jin Kim, Jiraporn Lueangsakulthai, Baidya Nath P. Sah, Brian Scottoline, David C. Dallas   +4 more
doaj   +1 more source

Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: a phase 1/2b randomized placebo-controlled trial

EClinicalMedicine, 2023
Summary Background Mucosal administration of monoclonal antibodies (mAbs) against respiratory pathogens is a promising alternative for systemic administration because lower doses are required for protection.
N. Mazur, Y. Löwensteyn, J. Terstappen, J. Leusen, Fred Schobben, Daniela Cianci, P. M. van de Ven, S. Nierkens, Louis J. Bont, Elisabeth E. Nibbelke, Brigitte J. M. Buiteman, Neele Rave, Marlies Vermaas—van Putten, Elly A. Smit-Kleinlugtenbeld, Jacqueline P. de Lege-Korstanje, Marieke G. Peetsold, Anthon Hulsmann, Sandy van Gool, Yvonne Snepvangers, Max Colombijn, N. Menelik, Stephanie de Crom, B. Semmekrot, W. D. de Waal, Eline Okhuijsen, Gavin W. ten Tusscher, R. de Moor, M. Breukels, Claire Lutterman, G. Tramper-Stranders, J. Oudshoorn, A. Ritman, Jeannette S. von Lindern, Gerdina H. Dubbink-Verheij, M. M. van den Berg, Marlon E. F. Wilsterman, Edwin Rietveld, Willemijn van Heel, Anne M. de Grauw, F. Croes, R. Doedens, Lonneke van Onzenoort-Bokken, C. B. Meijssen, Machteld van Scherpenzeel-de Vries, P. Hoekstra, Linda G. M. van Rooij, W. P. Boode, M. V. van Rossem, Petra Sipkema, Monique A M Jacobs, M. A. van Houten, Indrani Kok-Wijesinha, A. Vlieger, Walter Balemans, Frans B. Plötz, Naomi Reijmerink, Stefan M. van Dorth, Willem Heikens, Anke G. Kuijpers, Christel Geesing, B. Delsing, Mieke Aldenhoven, Károly Illy, E. Hack, F. Groenendaal, Nicole Derksen, K. Rengerink, J. Meeldijk, Lysette Ebskamp-van Raaij, J. D. D. de Groot-Mijnes, Rob Schuurman   +70 more
semanticscholar   +1 more source